Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific fasL+ CD4+ T cells: First evidence for lntratumor apoptotic regulatory T cells

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2686-2696

  Gritzapis, Angelos D ^a   Voutsas, Loannis F ^a   Lekka, Eftychia ^a   Papamichail, Michael ^a   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HELPER CELL; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; FEMALE; HLA-A2 ANTIGEN; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, REGULATORY; VACCINES, SUBUNIT;

EID: 77950805151     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2517     Document Type: Article

References (38)

1. Baxevanis CN, Sotiriadou NN, Gritzapis AD, et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol lmmunother 200655:85-95.
2. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/ neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 199050:4087-4091
3. Calogero RA, Cordero F, Forni G, Cavallo F. Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res 20079:211.
4. Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005201:1591-1602
5. Rolla S, Nicolo C, Malinarich S, et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006;177:7626-7633 (Pubitemid 44846277)
6. Lustgarten J, Dominguez AL, Cuadros C. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol 2004;34:752-761 (Pubitemid 39255923)
7. Mullins DW, Bullock TN, Colella TA, Robila W, Engelhard VH. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201- transgenic mice. J Immunol 2001167:4853-4860
8. Ambrosino E, Spadaro M, lezzi M, et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 200666:7734-7740
9. Gritzapis AD, Voutsas IF, Lekka E, et al. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol 2008181:146-154
10. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007;67:1326-1334 (Pubitemid 46270793)
11. Knutson KL, Dang Y, Lu H, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 2006;177:84-91. (Pubitemid 43939119)
12. Kono K, Rongcun Y, Charo J, et al. Identification of HER2/neuderived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998;78:202-208 (Pubitemid 28443178)
13. Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neuexpressing tumor cells in vivo. Cancer Res 2006;66:5452-5460 (Pubitemid 43844973)
14. Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer 2002;98:864-872 (Pubitemid 34286682)
15. Sotiropoulou PA, Perez SA, Voelter V, et al. Natural CDS+ T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors. Cancer Immunol lmmunother 2003; 52:771-779 (Pubitemid 37491705)
16. Rongcun Y, Salazar-Onfray F, Charo J, et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999163:1037-1044
17. Salazar LG, Fikes J, Southwood S, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003;9:5559-5565 (Pubitemid 37499475)
18. Sotiriadou R, Perez SA, Gritzapis AD, et al. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 200185:1527-1534
19. Voutsas IF, Gritzapis AD, Mahaira LG, et al. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the li-Key moiety of the invariant chain. Int J Cancer 2007; 121:2031-2041
20. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-2632 (Pubitemid 34575634)
21. Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. li-key/MHC class II epitope triple Tg: a strategy that enhances class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther 2006;6:1311-1321 (Pubitemid 44875685)
22. Pajot A, Michel ML, Fazilleau N, et al. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 2004;34:3060-3069 (Pubitemid 39549385)
23. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006116:1935-1945
24. Wang H, Peters T, Sindrilaru A, et al. TGF-β-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. J Clin Invest 2008;118:2629-2639 (Pubitemid 351949790)
25. + regulatory T cells during recovery from colitis via Fas/Fas ligandinduced death. J Immunol 2008180:8316-8326
26. Fritzsching B, Wang A, McKay DM. In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol 2005175:32-36
27. Koch M, Beckhove P, Op den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg 2006;244:986-992 (Pubitemid 44808640)
28. Gao Q, Qiu S J, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-2593 (Pubitemid 47041232)
29. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005102:18538-18543
30. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006313:1960-1964
31. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-280 (Pubitemid 43151547)
32. Nakajima C, Uekusa Y, Iwasaki M, et al. A role of interferon-γ (IFN-γ) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ-deficient mice. Cancer Res 2001 61:3399-3405
33. Lindencrona JA, Preiss S, Kammertoens T, et al. CD4+ T cellmediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004;109:259-264 (Pubitemid 38240929)
34. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003171:5787-5794
35. Quaglino E, lezzi M, Mastini C, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 200464:2858-2864
36. Lollini PL, Cavallo F, Nanni P, Fomi G. Vaccines for tumour prevention. Nat Rev Cancer 20066:204-216
37. Ashley CW, Baecher-Allan C. Responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B. J Immunol 2009; 183:4843-4847
38. Chen A, Liu S, Park D, Kang Y, Zheng G. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res 2007;67:1291-1298 (Pubitemid 46270789)